RNXT: RenovoCath's device shows strong adoption, survival benefit, and reduced toxicities in pancreatic cancer

RenovoCath's proprietary delivery system is driving rapid commercial adoption, with 21 centers active and a $400 million market opportunity. Interim phase III data show a 6-month survival benefit and 65% reduction in toxicities, supporting increased revenue guidance and expansion into new cancer in…